ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Case Report: Skin-Deep Eosinophils

Case Report: Skin-Deep Eosinophils

Vivek Mehta, MBBS, Sukhraj Singh, MD, Shubhasree Banerjee, MD, & Ruben Peredo-Wende, MD  |  May 17, 2018

Eosinophilia is usually defined as an eosinophil count of more than 500/microL in peripheral blood.1 An eosinophil count of more than 1,500 is referred to as hypereosinophilia (HE); hypereosinophilic syndrome (HES) is defined as HE associated with organ dysfunction attributable to eosinophilia.2 Eosinophilia can occur due to infectious, malignancy, autoimmune or allergic etiologies. However, a…

Filed under:Vasculitis Tagged with:Eosinophiliaeosinophilic disordersscabies

Generic-Drug Price Fixing: Is It Happening?

Philip Seo, MD, MHS  |  May 17, 2018

It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:generic competitiongeneric drug makersnot-for-profit generic drugmaker

IgG4-Related Kidney Disease: Diagnostics, Manifestations, & More

IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Despina Michailidou, MD, PhD, & Paul Cohen, MD   |  May 17, 2018

Immunoglobin G4-related disease (IgG4-RD) is a rare fibro-inflammatory disease of unknown etiology that has been recently recognized. It can cause fibro-inflammatory masses in almost every organ of the body and is associated with dense lymphoplasmacytic infiltration of IgG4-postitive plasma cells, storiform fibrosis and elevated levels of serum IgG4.1 IgG4-RD is a systemic disease that may…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:fibroinflammatoryIgG4 related diseaseIgG4-RDkidney disease

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Michele B. Kaufman, PharmD, BCGP  |  May 15, 2018

After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…

Filed under:Drug Updates Tagged with:celecoxib (Elyxyb)Drug SafetyfasinumabFDAhipkneeKnee Osteoarthritis (OA)Nonsteroidal anti-inflammatory drugs (NSAIDs)PainPain ManagementU.S. Food and Drug Administration (FDA)

Existing CT Scans as Good as DXA for Assessing Hip Fracture Risk

Scott Baltic  |  May 8, 2018

NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:computed tomographyCT scanOsteoporosisscan

FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine

Michele B. Kaufman, PharmD, BCGP  |  May 8, 2018

The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibFood and Drug Administrationhemophagocytic lymphohistiocytosisHLHlamotrigineU.S. Food and Drug Administration (FDA)

The Social Workers’ Role in Rheumatology Care & Patient Advocacy

Karen Appold  |  May 8, 2018

Patients with rheumatic disease require a team of specialists working together to meet the patient’s needs. Social workers can advocate for these patients and play a variety of other roles to help them manage their disease…

Filed under:Practice Support Tagged with:Association of Rheumatology Professionals (ARP)Care Teamhealthcare teampatient carepatient resourcessocial worker

Diclofenac May Boost MI Risk in Patients with Spondyloarthritis

Marilynn Larkin  |  May 7, 2018

NEW YORK (Reuters Health)—Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, but not in those who take naproxen, researchers say. Maureen Dubreuil, MD, MSc, of Boston University School of Medicine, and colleagues analyzed 20 years of medical records from the U.K.’s Health Improvement…

Filed under:Axial SpondyloarthritisConditions

Rheumatologists: Participate in the ABMS Certification Conversation

From the College  |  May 4, 2018

The ACR continues to actively advocate for certification reform and recently testified to the Continuing Board Certification: Vision for the Future Commission. The Commission is leading a collaborative effort to assess the current state of continuing board certification, and to envision a framework that is relevant and meaningful to physicians, patients, hospitals and health systems….

Filed under:From the College Tagged with:ABMS CertificationACR advocacyAdvocacyAmerican College of Rheumatology (ACR)future

International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2018

In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:adalimumabadult Still's Diseaseanakinraerythrodermic psoriasisguselkumabJapanplaque psoriasisPsoriasispustular psoriasis

  • « Previous Page
  • 1
  • …
  • 159
  • 160
  • 161
  • 162
  • 163
  • …
  • 329
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences